It now costs about $1 billion to get a new drug to market, or, if a company is unlucky, $1 billion to fail to get the drug to market. Like the movie…
The economic choppiness is coming to a head with the age of dividend hikes. The pressure is going to remain for companies to continue returning capital to shareholders while also looking for…
Markets opened slightly lower this morning and spent the morning trying to decide on a direction. The Reuters/University of Michigan Consumer Sentiment Index rose more than expected, but even that was not…
Novartis (NYSE: NVS) said it would cut 2,000 workers and outsource some functions to companies that will do the work for less than it can. Novartis will take a restructuring charge of…
A company can spend billions of dollars on R&D and get little respect as an innovator. Even though that is the conclusion of a new study by Booz & Co., the conclusion…
Drug maker Eli Lilly & Co. (NYSE: LLY) reported third-quarter earnings this morning, and the company did a little better than analysts expected, but worries persist that the company will be hit…
Sales for the big pharmaceutical companies are expected to be hit by pricing pressure in Europe, a lack of urgent new on the coming flu season, lower rates of prescription writing, and…
Angela Merkel faces a test: will her own party support money being used for the bailout of Greece? (Reuters) Bernanke says the Fed may have to act if inflation falls below targets.…
The 30-Year Treasury auction, the so-called Long Bond, had a strong participation for what is technically a 29-year and 11-month bond. The participation rate was strong enough that this still shows a…
Financial markets have been reeling as investors grow more concerned about the economy: An S&P downgrade of the full faith and credit of the United States, dismal GDP data, and ongoing weak…
Once patent protection expires on a prescription drug, the drug’s maker can take a serious beating in revenue and profitability. One way to make up for the loss is to get US…
Merck & Co. Inc. (NYSE: MRK) released second-quarter results last Friday and Pfizer Inc. (NYSE: PFE) reported this morning. The results of both drug behemoths are largely in line with analysts estimates…
Merck (NYSE: MRK) released an unusual earnings announcement. It is profitable, has a bright future, and will fire about 13,000 people. These employees can leave with the knowledge that they have helped…
Douglas A. McIntyre Earnings season is in full throttle and many major companies are due to report in the week ahead. Some of the key reports we are featuring for detailed earnings previews are the…
Many drug companies face a what is called a patent cliff ahead, where the Big Pharma players will have key drugs go off-patent and there will be new generic competition. While this…
